BACKGROUND: In patients with symptoms suggestive of cystic fibrosis (CF) and intermediate sweat chloride values (30-60 mmol/l), extensive CFTR gene mutation analysis and nasal potential difference (NPD) measurement are used as additional diagnostic tests and a positive result in either test provides evidence of CFTR dysfunction. To define the phenotype of such patients and confirm the validity of grouping them, patients with intermediate sweat chloride values in whom either additional CF diagnostic test was abnormal were compared with subjects in whom this was not the case and patients with classic CF. METHODS: The phenotypic features of four groups were compared: 59 patients with CFTR dysfunction, 46 with an intermediate sweat chloride concentration but no evidence of CFTR dysfunction (CF unlikely), 103 patients with CF and pancreatic sufficiency (CF-PS) and 62 with CF and pancreatic insufficiency (CF-PI). RESULTS: The CFTR dysfunction group had more lower respiratory tract infections (p = 0.01), more isolation of CF pathogens (p<0.001) and clubbing (p = 0.001) than the CF unlikely group, but less frequent respiratory tract infections with CF pathogens than the CF-PS group (p = 0.05). Patients in the CF-PS group had a milder phenotype than those with PI. Many features showed stepwise changes through the patient groups. CONCLUSION: Patients with intermediate sweat chloride values and two CFTR mutations or an abnormal NPD measurement have a CF-like phenotype compatible with CFTR dysfunction and, as a group, differ phenotypically from patients with intermediate sweat chloride values in whom further CF diagnostic tests are normal as well as from CF-PS and CF-PI patients.
BACKGROUND: In patients with symptoms suggestive of cystic fibrosis (CF) and intermediate sweat chloride values (30-60 mmol/l), extensive CFTR gene mutation analysis and nasal potential difference (NPD) measurement are used as additional diagnostic tests and a positive result in either test provides evidence of CFTR dysfunction. To define the phenotype of such patients and confirm the validity of grouping them, patients with intermediate sweat chloride values in whom either additional CF diagnostic test was abnormal were compared with subjects in whom this was not the case and patients with classic CF. METHODS: The phenotypic features of four groups were compared: 59 patients with CFTR dysfunction, 46 with an intermediate sweat chloride concentration but no evidence of CFTR dysfunction (CF unlikely), 103 patients with CF and pancreatic sufficiency (CF-PS) and 62 with CF and pancreatic insufficiency (CF-PI). RESULTS: The CFTR dysfunction group had more lower respiratory tract infections (p = 0.01), more isolation of CF pathogens (p<0.001) and clubbing (p = 0.001) than the CF unlikely group, but less frequent respiratory tract infections with CF pathogens than the CF-PS group (p = 0.05). Patients in the CF-PS group had a milder phenotype than those with PI. Many features showed stepwise changes through the patient groups. CONCLUSION:Patients with intermediate sweat chloride values and two CFTR mutations or an abnormal NPD measurement have a CF-like phenotype compatible with CFTR dysfunction and, as a group, differ phenotypically from patients with intermediate sweat chloride values in whom further CF diagnostic tests are normal as well as from CF-PS and CF-PIpatients.
Authors: George M Solomon; Michael W Konstan; Michael Wilschanski; Joanne Billings; Isabelle Sermet-Gaudelus; Frank Accurso; François Vermeulen; Elina Levin; Heather Hathorne; Ginger Reeves; Gina Sabbatini; Aubrey Hill; Nicole Mayer-Hamblett; Melissa Ashlock; John Paul Clancy; Steven M Rowe Journal: Chest Date: 2010-05-14 Impact factor: 9.410
Authors: Allison F McCague; Karen S Raraigh; Matthew J Pellicore; Emily F Davis-Marcisak; Taylor A Evans; Sangwoo T Han; Zhongzhou Lu; Anya T Joynt; Neeraj Sharma; Carlo Castellani; Joseph M Collaco; Mary Corey; Michelle H Lewis; Chris M Penland; Johanna M Rommens; Anne L Stephenson; Patrick R Sosnay; Garry R Cutting Journal: Am J Respir Crit Care Med Date: 2019-05-01 Impact factor: 21.405
Authors: Margaret Rosenfeld; Julia Emerson; Sharon McNamara; Valeria Thompson; Bonnie W Ramsey; Wayne Morgan; Ronald L Gibson Journal: J Cyst Fibros Date: 2012-05-01 Impact factor: 5.482
Authors: Manzoor A Raina; Mosin S Khan; Showkat A Malik; Ab Hameed Raina; Mudassir J Makhdoomi; Javed I Bhat; Syed Mudassar Journal: J Clin Diagn Res Date: 2016-12-01
Authors: Iram J Haq; Mike Althaus; Aaron Ions Gardner; Hui Ying Yeoh; Urjita Joshi; Vinciane Saint-Criq; Bernard Verdon; Jennifer Townshend; Christopher O'Brien; Mahfud Ben-Hamida; Matthew Thomas; Stephen Bourke; Peter van der Sluijs; Ineke Braakman; Chris Ward; Michael A Gray; Malcolm Brodlie Journal: Am J Physiol Lung Cell Mol Physiol Date: 2020-12-09 Impact factor: 5.464